Mast Therapeutics, Inc. (MSTX)

[RNsidersbuying]

Importantly, vepoloxamer has the potential to become the first and only approved therapy for shortening the duration of a sickle cell vaso-occlusive crisis and we are working diligently toward generating top-line results, which we expect to announce this quarter," continued Mr. Culley.

Or within about 45 days? Should get more interesting here very soon as I see the downside on an EPIC failure at about .15 maximum with the upside, maybe 1.00 or more?

Still holding my several year's accumulated core and just missed adding new flippers at .233 a few weeks back.